2026-03-05 10:02Financial Data and Key Metrics Changes - In 2025, the company's revenue reached RMB 73.4 billion, representing a year-over-year increase of 26.3% [7][18] - Non-IFRS profit totaled RMB 6.5 billion, up 36.3% year-over-year, with a non-IFRS profit margin of 8.9% [8][25] - The fourth quarter revenue was RMB 21 billion, reflecting a year-over-year increase of 27.4% [7][18] Business Line Data and Key Metrics Changes - Direct sales revenue reached RMB 16.9 billion in 2025, up 24.8% year-over-year, accounting for 82.9% of total revenue [19] - Service revenue increased to RMB 12.6 billion, up 34.1% year-over-year, representing 17.1% of total revenue [19] - The company introduced over 100 new drugs in 2025, a significant increase from 13 in 2024 [8] Market Data and Key Metrics Changes - The annual active user accounts reached approximately 220 million, with an addition of 34 million compared to the previous year [18] - The company established over 300 self-operated pharmacies nationwide, integrating them with on-demand retail services [12] Company Strategy and Development Direction - The company aims to deepen its presence in key healthcare segments through an omnichannel approach and AI-powered healthcare services [6] - Future growth will focus on expanding partnerships with pharmaceutical companies and enhancing the user experience through innovative health solutions [9][15] - The company plans to leverage its supply chain strengths and direct sales capabilities to maintain leadership in the healthcare retail market [15] Management Comments on Operating Environment and Future Outlook - The management expressed confidence in the company's growth potential, citing a large market size of RMB 3 trillion-4 trillion for the pharmaceutical sector [30] - The company is committed to enhancing user experiences and improving cost efficiency through AI technologies [26] - Management highlighted the importance of a steady and cautious approach to offline business expansion, emphasizing the integration of AI in healthcare services [49] Other Important Information - The company achieved a growth margin of 24.8% in 2025, up 1.9 percentage points year-over-year [22] - The fulfillment expense ratio was 10.4%, and the selling and marketing expense ratio remained flat at 5.2% [23] - Cash flow from operating activities reached RMB 10.2 billion for the full year [25] Q&A Session Summary Question: Near term and three-year middle term prospects - Management indicated that the pharmaceutical sector, health products, and medical devices present significant growth opportunities, with plans to deepen engagement with pharmaceutical companies and enhance product offerings [29][30][34] Question: Competition landscape - Management expressed confidence in the company's ability to stand out among competitors by leveraging supply chain management and maintaining high product quality [40][41] Question: Plans for brick-and-mortar stores and M&A - Management clarified that there are no plans for large-scale M&A but emphasized the importance of offline practices and the integration of pharmacies to enhance user experiences [43][44][46]